Bank of New York Mellon’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-240,919
| Closed | -$5.19M | – | 4202 |
|
|
2025
Q4 | $5.19M | Sell |
240,919
-7,232
| -3% | -$140K | ﹤0.01% | 2310 |
|
|
2025
Q3 | $3.79M | Sell |
248,151
-3,688
| -1% | -$48K | ﹤0.01% | 2482 |
|
|
2025
Q2 | $2.23M | Buy |
251,839
+17,719
| +8% | +$156K | ﹤0.01% | 2693 |
|
|
2025
Q1 | $1.83M | Buy |
234,120
+9,025
| +4% | +$75.6K | ﹤0.01% | 2739 |
|
|
2024
Q4 | $2.37M | Sell |
225,095
-971
| -0.4% | -$11.8K | ﹤0.01% | 2691 |
|
|
2024
Q3 | $2.96M | Sell |
226,066
-99,322
| -31% | -$1.51M | ﹤0.01% | 2565 |
|
|
2024
Q2 | $4.57M | Buy |
+325,388
| New | +$5.3M | ﹤0.01% | 2384 |
|
|
2017
Q2 | – | Sell |
-1,776,969
| Closed | -$17.2M | – | 4298 |
|
|
2017
Q1 | $17.2M | Sell |
1,776,969
-6,142
| -0.3% | -$61.4K | ﹤0.01% | 1635 |
|
|
2016
Q4 | $18.5M | Buy |
1,783,111
+7,524
| +0.4% | +$82.7K | 0.01% | 1581 |
|
|
2016
Q3 | $22M | Sell |
1,775,587
-42,992
| -2% | -$562K | 0.01% | 1403 |
|
|
2016
Q2 | $19.5M | Sell |
1,818,579
-1,923,365
| -51% | -$20.5M | 0.01% | 1417 |
|
|
2016
Q1 | $41.3M | Buy |
3,741,944
+1,122,072
| +43% | +$11.1M | 0.01% | 977 |
|
|
2015
Q4 | $32M | Buy |
2,619,872
+820,691
| +46% | +$12.8M | 0.01% | 1083 |
|
|
2015
Q3 | $29.3M | Sell |
1,799,181
-89,419
| -5% | -$1.97M | 0.01% | 1164 |
|
|
2015
Q2 | $40M | Buy |
1,888,600
+553,825
| +41% | +$9.93M | 0.01% | 1034 |
|
|
2015
Q1 | $24M | Buy |
1,334,775
+1,162,189
| +673% | +$18.2M | 0.01% | 1363 |
|
|
2014
Q4 | $2.96M | Sell |
172,586
-34,733
| -17% | -$496K | ﹤0.01% | 2603 |
|
|
2014
Q3 | $2.97M | Sell |
207,319
-83,560
| -29% | -$1.2M | ﹤0.01% | 2614 |
|
|
2014
Q2 | $4.36M | Sell |
290,879
-58,650
| -17% | -$707K | ﹤0.01% | 2401 |
|
|
2014
Q1 | $4.68M | Buy |
349,529
+52,876
| +18% | +$567K | ﹤0.01% | 2342 |
|
|
2013
Q4 | $2.39M | Buy |
296,653
+46,728
| +19% | +$330K | ﹤0.01% | 2783 |
|
|
2013
Q3 | $1.64M | Buy |
249,925
+24,488
| +11% | +$151K | ﹤0.01% | 2975 |
|
|
2013
Q2 | $1.38M | Buy |
+225,437
| New | +$1.16M | ﹤0.01% | 2996 |
|
Other funds holding AVDL
Bank of New York Mellon's AVDL Position: Q1 2026 in Review
Bank of New York Mellon sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 240,919 shares — an estimated $5.19M sold.
Bank of New York Mellon first reported a position in AVDL in Q2 2013 and held it in 23 quarters. The position peaked at $41.3M in Q1 2016. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Bank of New York Mellon reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 240,919 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.19M.
- Bank of New York Mellon first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 23 quarters.
- Bank of New York Mellon's Avadel Pharmaceuticals position peaked at $41.3M in Q1 2016.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.